BA
CPIX icon

Ballew Advisors’s Cumberland Pharmaceuticals CPIX Stock Holding History

Ballew Advisors’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,557
Closed -$31K – 150
2018
Q3 		$31K Sell
5,557
-43
-0.8% -$253 0.03% 201
2018
Q2 		$34K Hold
5,600
– – 0.04% 190
2018
Q1 		$37K Buy
+5,600
New +$38.5K 0.03% 181

Other funds holding CPIX

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Ballew Advisors's CPIX Position: Q4 2018 in Review

Ballew Advisors sold out of Cumberland Pharmaceuticals (CPIX) in Q4 2018, closing a stake of 5,557 shares — an estimated $31K sold.

Ballew Advisors first reported a position in CPIX in Q1 2018 and held it in 3 quarters. The position peaked at $37K in Q1 2018. 27 funds tracked by Wall St. Rank hold CPIX as of Q4 2018.

  • Ballew Advisors reported no remaining Cumberland Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Ballew Advisors sold 5,557 Cumberland Pharmaceuticals shares in Q4 2018, an estimated $31K.
  • Ballew Advisors first reported a position in Cumberland Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Ballew Advisors's Cumberland Pharmaceuticals position peaked at $37K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.